Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient

HLA-B*5701 Correlations

Slide 12

November 2008

However, there is a significantly lower odds ratio, down to 0.03, for abacavir hypersensitivity reactions by prospective screening for HLA-B*5701 allele in immunologically-confirmed hypersensitivity reactions.

Prospective screening and exclusion of patients with the HLAB*5701allele reduces the incidence of abacavir hypersensitivity reactions.

HLA-B*5701 Correlations


Jump to section: